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Background: Alcohol use disorders and social anxiety disorder are common and disabling conditions that
frequently co-exist. Although there are efficacious treatments for each disorder, only two randomized controlled
trials of interventions for these combined problems have been published. We developed a new integrated
treatment for comorbid Social Anxiety Disorder and Alcohol Use Disorder based on established Motivational
Interviewing (MI) and Cognitive Behaviour Therapy (CBT) interventions for the separate disorders. Compared to
established MI/CBT for alcohol use disorders this new intervention is hypothesised to lead to greater reductions in
symptoms of social anxiety and alcohol use disorder and to produce greater improvements in quality of life. Higher
levels of alcohol dependence will result in relatively poorer outcomes for the new integrated treatment.
Methods/design: A randomised controlled trial comparing 9 sessions of individual integrated treatment for alcohol
and social phobia with 9 sessions of treatment for alcohol use problems alone is proposed. Randomisation will be
stratified for stable antidepressant use. Post treatment clinical assessments of alcohol consumption and diagnostic
status at 3 and 6 month follow-up will be blind to allocation.
Discussion: The proposed trial addresses a serious gap in treatment evidence and could potentially define the
appropriate treatment for a large proportion of adults affected by these problems.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12608000228381.
Keywords: Alcohol use disorders, Social anxiety disorder, Comorbidity, Cognitive behavior therapy, Clinical trialBackground
Comorbid alcohol use disorders and social phobia (or
social anxiety disorder) are common and disabling con-
ditions. Although there are efficacious treatments for
each disorder, little is known about the best way to treat
these disorders when they co-exist. Genetic epidemi-
ology [1], and basic cognitive and behavioural science* Correspondence: andrew.baillie@mq.edu.au
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reproduction in any medium, provided the or[2,3] suggest these two disorders interact rather than
simply co-occur. There are currently two randomized
controlled trials of interventions for these combined
disorders [4,5] showing that focusing on alcohol alone
produces superior outcomes than a focus on both disor-
ders simultaneously. However, neither study integrated
evidence based treatments for the separate disorders.
Randall et al. [4] used a social phobia treatment program
of unknown effectiveness with severe “alcoholics”, while
Schadé et al. [5] tested an intervention targeting alcohol
and phobias that we will argue was poorly integrated.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for comorbid Social Anxiety and Alcohol Use Disorders
based on established Motivational Interviewing (MI) and
Cognitive Behaviour Therapy (CBT) interventions for
the separate disorders in a randomized controlled trial.
Its findings have the potential to provide valuable infor-
mation to service providers regarding the treatment
needs of people with these combined problems.
Epidemiological research has shown that alcohol use
disorders and social phobia are prevalent mental health
problems in the community, affecting one in four and
one in seven people respectively in their lifetime [6]. We
have also reported the significant lifetime and concur-
rent comorbidity of these disorders [6-8]. In population
samples, between one-fifth and one-third of people with
an alcohol use disorder have social phobia in their life-
time, and over one-third of those with social phobia
have alcohol use disorders in their lifetime [1,9-11].
These studies have typically found a closer association
with alcohol dependence than abuse and an age at onset
of social phobia that predates that of alcohol use disor-
ders [1,12].
Teesson and colleagues reported 12-month prevalence
rates for mental health comorbidity among the 10,641
Australian adults in the National Survey of Mental
Health and Wellbeing [6,8,13]. They found that 3.7% of
people with an alcohol use disorder also had social pho-
bia, and 16% of those with social phobia had an alcohol
use disorder. The odds ratio of the association between
the two disorders was 3.2 (95% confidence interval 1.8-
5.8) [8]. Respondents with alcohol use disorders and
comorbid mental health problems were significantly
more disabled and more likely to use health services
than respondents with an alcohol use disorder and no
comorbidity [8].
Comorbid social anxiety and alcohol use disorder are
more common and disabling in clinical than population
samples [14-17]. Although the nature of the relationship
between anxiety disorders and alcohol use problems has
been the object of some debate, recent evidence suggests
consistently that social phobia is primary and substance-
independent and has an age at onset in early adoles-
cence, typically before the onset of alcohol use problems
[1,18-21].
Despite several comprehensive reviews of the relevant
literature, explanations for this relationship between al-
cohol use problems and anxiety disorders remains un-
clear. Broadly theories can be grouped into those that
propose alcohol to be primary, others that see anxiety as
primary, and those that see the two disorders as
interacting. As it is clear that the acute effects of alcohol
consumption and alcohol withdrawal can increase
anxiety levels, some have argued that alcohol anxiety co-
morbidity is illusory [22,23]. Such an argument mayapply more to anxiety symptoms that would otherwise
be diagnosed as panic disorder or generalised anxiety
disorder because of alcohol’s effect on arousal. As avoi-
dance and other phobic behaviour in both social phobia
and agoraphobia is related to but not determined by
arousal it is harder to explain away these phobias as a
direct effect of alcohol.
The tension reduction hypothesis [24] and the self
medication hypothesis [25] both propose that alcohol is
consumed because of its sedative effects. Many of the
simpler theoretical models developed to explain the link
between anxiety symptoms and alcohol use disorders
(e.g., Tension Reduction, Stress Response Dampening,
and Self-Medication) fail to consider that alcohol is a
drug of addiction so that once developed alcohol prob-
lems may be maintained by processes other than anxiety.
Thus alcohol problems may persist beyond treatment of
the anxiety disorder [2]. Once comorbidity is established,
alcohol use problems act to maintain or worsen anxiety
disorders. Alcohol, specifically alcohol withdrawal, may
directly induce symptoms of anxiety, while intoxication
in the face of phobic stimuli may inhibit habituation of
conditioned fear responses or disconfirmation of inflated
threat expectancies that are thought to underlie anxiety
disorders. Thus, while many expect alcohol will calm
their anxiety, it probably acts to maintain anxiety disor-
ders [26]. For these reasons, Kushner et al. [3] postulated
that short-term anxiety reduction from alcohol use, to-
gether with long-term anxiety induction from chronic
drinking and withdrawal, can initiate a vicious cycle of
increasing anxiety symptoms and alcohol use that
sustains these comorbid disorders. One hypothesis that
emerges from this model is that to be effective, treat-
ment would need to conceptualise the interaction bet-
ween anxiety and drinking and treat the cognitions and
behaviour relating to the both disorders in an integrated
manner. The posposed trial will be the first to do this.
There are brief interventions [27,28] available for
individuals with alcohol use problems that are supported
by empirical evidence and have demonstrated cost-
effectiveness [29]. Whether these interventions result in
clinically significant improvement in individuals with co-
morbid problems remains to be determined [30]. There
are few studies that have addressed the impact of comor-
bid anxiety disorders on alcohol treatment outcome
[31-37]. Overall, their results suggest that comorbidity is
associated with worse alcohol treatment outcome, relapse
and readmissions [36,37]. Driessen and colleagues [31]
examined the association between drinking behaviour and
the course of anxiety and depression in 100 alcohol
dependent patients with and without these comorbid
disorders during the early and late post-detoxification
periods. At six months post-treatment abstinence rates dif-
fered significantly between groups (60.5% non-comorbid vs
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alone comorbidity). Although not definitive, it appears that
comorbid anxiety disorders may be associated with a
poorer treatment outcome for alcohol dependence.
There are also efficacious empirically supported CBT-
based treatments for social phobia [38-43]. However, be-
cause anxiety treatment trials usually exclude individuals
with substance use problems the efficacy of the anxiety
treatment cannot be assumed to generalise to individuals
with comorbid substance use disorders. To our know-
ledge, only one study to date has specifically examined
the impact of a co-morbid alcohol use disorder on social
phobia treatment outcomes. McEvoy and Shand [44]
showed that severity of pre-treatment alcohol misuse
independently predicted change in social interaction
anxiety, but not performance anxiety.
Two randomised controlled trials have explored the
efficacy of treatment for alcohol use problems and co-
existing social phobia [4,5]. In the first RCT of alcohol
use disorders and social phobia [4], individuals meeting
DSM-III-R criteria for these disorders were recruited
from among outpatients seeking treatment for alcohol
use problems. Participants were randomised to one of
two treatment conditions: 12 weeks of individual CBT
treatment for alcohol dependence or 12 weeks of
treatment for both alcohol and social phobia. Data were
collected at the end of treatment and 3 months later.
Participants in both treatment conditions improved
significantly on social phobia and alcohol measures.
However, the concurrent treatment group had a signifi-
cantly poorer outcome on some alcohol measures com-
pared to the alcohol only group: participants drank more
frequently, had more heavy drinking days, and drank
more drinks than participants who received alcohol
treatment only. Although there were no significant
differences in rates of attendance between the two groups,
more participants completed all 12 dual treatment ses-
sions than alcohol only sessions (43% versus 32%).
The unexpected finding of worse alcohol outcome in
the dual treatment group in Randall et al. [4] was attrib-
uted to several limitations, including: parallel presenta-
tion of two unintegrated manualized treatments, in
which alcohol was addressed during the first 45 minutes
of each session and social phobia in the next 45 minutes;
and a loss of alcohol treatment time in the dual treat-
ment condition. The authors comment that the sample
was drawn from a “severe population of treatment
seeking alcoholics” (p 218). It is possible those with
more severe alcohol dependence may not do as well if
they are distracted from a focus on their treatment for
alcohol dependence. In addition the intervention for so-
cial phobia was based on an unpublished treatment
manual that had not previously been evaluated. This
intervention may have constituted suboptimal socialphobia treatment and an intervention supported by
empirical evidence may have yielded different results.
The findings of worse alcohol outcomes following dual
treatment are surprising and merit replication.
The second study of alcohol and phobias [5] was a
randomised controlled trial of 96 abstinent alcohol
dependent patients with comorbid social phobia or
agoraphobia. The patients were randomly assigned to an
intensive, comprehensive 32 week psychosocial program,
involving 3–4 months of inpatient groups followed by up
to 16 weeks of aftercare, relapse-prevention and disulfiram
on its own or in combination with an anxiety treatment
program comprising CBT and optional pharmacotherapy.
The anxiety treatment consisted of 12 weekly 60-minute
sessions of cognitive therapy delivered individually at an
anxiety clinic; the first six sessions of treatment dealt with
alcohol only. The authors found that additional therapy
for anxiety significantly reduced anxiety symptoms and
avoidance behaviour but did not affect the alcohol relapse
rates. While 13 of the 49 (26.5%) who were allocated to
Alcohol only treatment were abstinent for 30 days before
each of the three assessments, 18 of the 47 (38.3%) who
were allocated to alcohol and anxiety treatment were
similarly abstinent giving an effect size of 0.13. While this
difference was not statistically significant, there was only a
23.4% chance that this size of effect would be detected
with the sample size employed. In addition there was a
trend of greater reduction of heavy drinking days in the
dual treatment group: the reduction in mean number of
days drinking 5 or more drinks from baseline to follow-up,
was greater (not significantly) in the combined (mean re-
duction 9.4) than in the alcohol only treatment (mean 7.1).
The inclusion of both panic/agoraphobia and social phobia
comorbid with alcohol leaves the results less clear. The
genetic epidemiology [1] suggests that while alcohol use
disorders and panic disorder may share vulnerability, social
anxiety and drinking have distinct vulnerabilities. Thus, the
processes that maintain comorbid disorders may be differ-
ent and thus require different treatment. It may also be
that patients who require eight months of treatment for
alcohol may require more than the six sessions of cognitive
therapy for social phobia provided in this trial and, con-
versely, that those who have less chronic or severe alcohol
problems may derive greater benefits from dual treatment
than did patients in the above study.
These studies suggest that treating anxiety disorders in
alcohol dependent patients undergoing alcohol treat-
ment improves the anxiety disorder but may not yield
superior alcohol treatment outcomes relative to alcohol
treatment alone. The results of the above two trials are
not definitive. The first study [4] employed a previously
unevaluated intervention for social phobia and delivered
treatment in a parallel and unintegrated manner to a
sample of severe treatment seeking “alcoholics”. In the
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different clinic by different clinicians to patients with
both social anxiety and panic/agoraphobia. Thus, these
studies may not constitute optimal tests of integrated,
empirically based interventions for these prevalent
problems.
If ongoing anxiety problems have a deleterious impact
on the maintenance of alcohol treatment effects then it
is important that efficacious treatment be identified. The
present study aims to test the efficacy of an empirically
supported intervention for social phobia integrated with
an existing well-established CBT intervention for alcohol
use problems supported by empirical evidence. The
treatment will be tested in a sample of participants with
a range of severity of alcohol problems from consump-
tion at harmful levels to alcohol dependence.
Cognitive behaviour therapy has been demonstrated to
be an effective treatment for Social Phobia [45-51]. Some
of the effective CBT interventions are based on Rapee
and Heimberg’s [50] cognitive model for the mainten-
ance of social phobia. The model proposes that indivi-
duals with social phobia experience distortions and
biases in the processing of social or evaluative informa-
tion which lead to increased anxiety and help to main-
tain social phobia. According to the model, treatment
involves redirecting attentional resources away from the
mental representation of how the individual appears to
the audience and indicators of negative evaluation from
the audience and towards the task at hand and more
positive aspects of the audience. The model emphasises
the importance of cognitive restructuring and objective
feedback of performance as well as instruction and
feedback regarding avoidance behaviours when exposure
is undertaken. Alcohol use, in Rapee and Heimberg’s
[50] model, is construed as an avoidance behaviour or a
means of self handicapping [52]. A person with social
phobia would learn to use alcohol as a safety behaviour
and avoidance strategy in social or evaluative situations
in an attempt to make the situation easier to cope with.
Alternatively, Alcohol use would allow a face saving
excuse for their perceived or actual poor social perfor-
mance (self-handicapping). The acute effects of alcohol
in a social situation could also reduce attentional
resources so that corrective information about actual
performance or the responses of others is ignored. With
continued use of alcohol, anxiety and depression would
increase and further reinforce beliefs that they are
incompetent and poorly skilled [50]. This package of
treatment is of known efficacy and is likely to be more
effective than the previously unproven intervention used
in the Randall et al. [4] trial.
There are also effective pharmacological [53,54] and
psychological treatments for alcohol use disorders. Our
own research [53], and that reported in recent a largeUS trial [54] has found naltrexone to be effective in
reducing drinking in some with alcohol dependence.
Naltrexone is a non-specific opioid antagonist with high
affinity for the mu-opioid receptor, which is hypothe-
sised to be the principal site of action. Chronic alcohol
abuse has been linked to increased endogenous opioids,
and naltrexone has been found to reduce the craving
[55] and the ‘high’ produced by alcohol in humans [56].
The majority of controlled clinical trials have shown a
significant advantage of naltrexone over placebo in the
prevention of relapse to heavy drinking [53,54,57]. While
other studies have not shown benefit over placebo
[58,59] we believe there is sufficient evidence to offer all
participants a trial of naltrexone (50 mg, 1 tablet daily)
unless contraindications are present [60,61].
Baillie and Sannibale [62] have developed integrated
cognitive behavioural treatment for comorbid alcohol
and anxiety disorders and we further review the research
and clinical rationale for the specific intervention
strategies in Stapinski et al. [63]. This paper documents
the protocol for evaluating the combined integrated
MI/CBT for comorbid social anxiety and alcohol use
disorders.
Methods/Design
The proposed study is a randomised controlled trial
which aims to determine the relative efficacy of an inte-
grated intervention, BT for social phobia and co-existing
alcohol use problems (Combined Alcohol Social Phobia;
CASP) compared with CBT for alcohol use problem
alone (Alcohol Alone). The study was funded by a
National Health and Medical Research Council Project
Grant (#488508) to the authors and was reviewed and
approved by Macquarie University Ethics Review Com-
mittee (Human Research) HE28MAR2008-R05758 and
by Sydney South Western Area Health Service, Ethics
Review Committee (RPA Zone) X09-0331 & HREC/09/
RPAH/553.
Objective
The proposed study aims to determine the relative
efficacy of an integrated individual cognitive behaviour
therapy (CBT) for alcohol use problems and social
phobia compared with individual CBT targeting alcohol
use problems alone for people with social phobia and
alcohol problems.
Hypotheses
1. Participants who receive treatment for
alcohol use problems alone will show reductions
in alcohol consumption and symptoms of
social phobia and improvements on secondary
outcomes.
Figure 1 Consort style flowchart. Notes: #1 Potential participants
who are excluded because of likely need for assistance in
withdrawal are eligible to enter the study after successful withdrawal
at the point of the clinical assessment.
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for alcohol use problems and social phobia will show
significantly greater improvements in terms of
alcohol consumption, social phobia and quality of
life compared with those in the alcohol treatment
alone. They will maintain a lower rate of alcohol
consumption for longer than the alcohol treatment
alone group and will have greater improvements on
measures of general health and functioning.
3. Participants in the integrated treatment condition
will have a lower rate of treatment attrition than
participants in the alcohol treatment alone
intervention.
4. Higher levels of alcohol dependence will result in
relatively poorer outcomes for the integrated
treatment.
Trial design
This is a randomised controlled trial utilising individual
level randomisation to either combined treatment for
alcohol and social phobia or treatment for alcohol use
problems alone. Randomisation will be stratified for
baseline Antidepressant use.
Sample
To ensure that the full range of severity of alcohol prob-
lems and social phobia are included in the sample,
recruitment will include screening in a range of health
services (General Practice and specialist drug and
alcohol and anxiety clinics) and advertising in media.
Co-ordination of the trial and a telephone point of
contact will be at the Centre for Emotional Health,
Macquarie University (AJB, LS & RR). A CONSORT
style flow chart is shown in Figure 1.
Recruitment
Specialist alcohol and social phobia treatment services
will be asked to screen all new presentations with the
Alcohol Use Disorders Identification Test [64] and the
Mini-SPIN [65] and contact the research team when
there is a positive screen on both tests. Advertisements
and media coverage will point potential participants to
online versions of these two questionnaires or direct
telephone screening.
Inclusion/exclusion criteria
Participants will be adults (aged 18 years and older) who
consume alcohol at harmful levels [66] (men consuming
29 standard drinks of alcohol per week or more and
women 14 standard drinks per week or more), have a
current (DSM-IV) diagnosis of social anxiety disorder
and, have a basic literacy and ability to communicate in
English to ensure comprehension and ability to complete
reading and written take-home tasks.Exclusion criteria for the study are: i) Active or florid
psychosis (assessed using the Psychosis Screening
Questionnaire [67]) or clinician suspicion following Anxiety
Disorders Interview Schedule for DSM-IV (ADIS-IV)
[68]. ii) History of schizophrenia spectrum disorder or
bipolar disorder. iii) Current active suicidal intent (also
assessed by a Clinical Psychologist with the ADIS-IV
Anxiety Disorders Interview Schedule for Clinical diagno-
sis and Assessment of suicidal ideation). iv) Current
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Index, OTI) [69] v) Dependence on benzodiazepines or
other substances (other than tobacco) (OTI) vi) Need for
intensive detoxification (a score ≥ 20 on CIWA-AR [70])
(upon completion of detoxification participants will be
eligible for inclusion); and vii) Inability to provide locator
information or inability to participate in treatment and
booster sessions (eg impending likelihood of imprison-
ment or residential treatment).
Given the high use of SSRI and other antidepressant
medication in this population, the study population will
be stratified into those who are taking antidepressants
and those who are not. Patients who report regular use
of antidepressant medication for at least one month, will
be asked to remain on a stable dose during treatment.
Patients taking these medications irregularly and without
clear benefit will be asked to discontinue for two weeks
prior to assessment for this study in consultation with
the prescribing doctor.
Assessment
Prospective participants will first contact the investiga-
tors by telephone for initial screening and if likely to be
suitable they will be asked to complete questionnaires
online via the Survey Monkey website and attend for an
initial clinical assessment at either the Emotional Health
Clinic at Macquarie University (AJB, LS, RR) or Drug
Health Services at Royal Prince Alfred Hospital (CS, PH).
Participants who meet inclusion criteria will be asked to
reduce their drinking to “low risk” levels as recommended
by NHMRC [66] (males up to 4 standard drinks per day
and women up to 2 standard drinks per day) for three
days to minimise the transient effects of alcohol use on
functioning (e.g., intoxication, anxiety, irritability, sadness
and depressed mood) [23,71].
Participants who are likely to require withdrawal
management (severe alcohol dependence, previous
withdrawal, current score ≥ 20 on CIWA-AR indicat-
ing established withdrawal) [70] will be referred to
local specialist drug and alcohol clinics or partici-
pating general medical practitioners (selected GPs
who have been made aware of this study and are
willing to provide treatment for study participants).
Once withdrawal is completed and the prospective
participant has achieved 3 days of no more than low
risk drinking, they are invited for the initial clinical
interview.
The initial clinical assessment will include the Anx-
iety Disorders Interview Schedule for DSM-IV (ADIS-
IV) [68] and be conducted by a Masters or PhD level
Clinical Psychologist. In previous research [51] we have
demonstrated high inter-rater reliability for social
anxiety disorder (kappa = 0.87) and anxiety disorders in
general (kappa = 0.80) using this interview. Participantswill also be assessed using questions based on the
Avoidant Personality Disorder section of the Interna-
tional Personality Disorder Examination (IPDE) [72].
All interviews will be audio-taped and a random
sample of 25% will be rated by a PhD level Clinical
Psychologist with relevant diagnostic experience, to
determine diagnostic reliability. Measures used in the
study are shown in Table 1 and include: the Anxiety
Sensitivity Index [73]; Kushner’s Alcohol Outcome
Expectancies Questionnaire [74]; the Timeline Follow-
Back (TLFB) method for quantifying alcohol consumption
over the previous 28 days [75,76]; the Opiate Treatment
Index (OTI) to assess drug (and medication) quantity and
frequency during the previous 28 days [69]; the Penn
Craving Scale [77]; Self efficacy for abstinence [78]; the
University of Rhode Island Change Assessment [79],
used to assess motivation; Health Service Utilisation
questions [80], used to asses other treatment received
in study period.
Blood will be taken for full blood count (FBC), liver
function tests (LFTs) and carbohydrate-deficient trans-
ferrin (CDT; a biological marker of recent alcohol
consumption), calcium and electrolytes at baseline. If
abnormal test results are obtained at baseline when self
reported alcohol consumption is at harmful or hazard-
ous levels blood will also be taken at follow-up. If there
are no abnormalities at baseline with self reported
alcohol consumption at harmful or hazardous levels no
blood will be taken at follow-up as repeat testing not
clinically indicated and not informative as a measure of
alcohol consumption.Primary outcome measures
The primary outcomes for social anxiety disorder will
be reductions in measures of social anxiety disorder:
the Social Phobia Scale and Social Interaction Anxiety
scale [83]. The primary outcome measures for alcohol
are a reduction in the number of standard drinks per
drinking day, assessed using the TLFB [75,76] and in
the Severity of Alcohol dependence Questionnaire
(SADQc) [84]. Quality of Life will be assessed by the
SF12 [85].Secondary outcome measures
Secondary outcome measures are: the number (propor-
tion) of days abstinent during the past 90 days; two time
to event measures: (i) time to first drink; (ii) time to first
heavy drinking day “relapse”, defined as three consecutive
days drinking ≥ 6 standard drinks for a man and ≥ 4 stand-
ard drinks in a day for women) assessed using the TLFB
[75,76]; the Depression, Anxiety and Stress Scale scores
[87], and Days out of role from the Brief Disability
Questionnaire [88].














Alcohol Use Disorders Identification Test (AUDIT) [64] + - - - - -
Mini Social Phobia Inventory (Mini-SPIN) [65] + - - - - -
Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-AR) [70] + - - - - -
Suicide Behaviours Questionnaire-Revised (SBQ-R) [81] + - - - - -
Psychosis Screening Questionnaire [67] + - - - - -
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) [82] incorporating
International Personality Disorders Examination Avoidant Personality
Disorder questions (IPDE) [72]
- + - - + -
Primary outcome measures
Social Phobia Scale and Social Interaction Anxiety Scale (SPS/SIAS) [83] - + + + + +
Time Line Follow Back (TLFB) [76] - + + + + +
Severity of Alcohol Dependence Questionnaire (SADQc) [84] - + + + + +
General Health functioning SF12 [85]. - + - + + +
Blood for LFTs, FBC, CDT, Electrolytes - + - - +(1) -
Secondary outcome measures
Sheehan Disability Scale(SDS) [86] - + - + + +
Depression, Anxiety and Stress Scale (DASS-21) [87] - + + + + +
Days out of role from the Brief Disability Questionnaire [88] - + - + + +
Drinker Inventory of Consequences (DRINC) [89] - + - + + +
Static and varying covariates
Family Tree Questionnaire (FTQ) +
Anxiety Reduction Subscale of the Alcohol Expectancies Questionnaire [90] - + - + + +
Kushner’s Alcohol Outcome Expectancies Questionnaire [74] - + - + + +
Penn Alcohol Craving Scale(PACS) [77] - + - + + +
Alcohol Abstinence Self Efficacy Scale (AASES) [78] - + - + + +
Alcohol Expectancies for Social Evaluative Situations scale (AESES) [91] - + - + + +
Anxiety Sensitivity Index (ASI) [73] - + - + + +
University of Rhode Island Change Assessment (URICA) [79] - + - + + +
Potential confounds
Health Service Utilisation questions [80] - + - + + +
The Opiate Treatment Index (OTI) [69,92] - + - + + +
Notes (1) Blood tests were used to verify abstinence only if baseline tests were elevated when drinking was reported.
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After baseline assessment, all participants will complete a
pre-treatment session of motivational interviewing followed
by a 1 month “washout” period of abstinence. Symptoms
of social anxiety (SPS and SIAS), general anxiety and
depression (DASS) will then be reassessed. After reading
and signing a written information and consent form,
participants will be individually randomised by the sealed
envelope method to one of two treatment conditions, of
either: i) Treatment for alcohol use disorder comprising 9
weekly sessions of individual CBT for alcohol use disorder;
OR ii) Treatment for alcohol use disorder and social
anxiety disorder comprising 9 weekly sessions ofintegrated individual CBT for alcohol use disorder and
anxiety disorder.
Each therapy session will last 60 to 90 minutes and
will be conducted by one therapist (Clinical Psychologist).
Both treatment conditions will have the same therapists
and equal exposure to face-to-face treatment, approxi-
mately 10–15 hours, over a total of approximately three to
five months.
Participants will be encouraged to attend treatment
sessions weekly where possible, but will be given a max-
imum time frame of 5 months from initial assessment in
which to complete treatment. Post and follow up assess-
ment time points will be calculated from the end of all
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plus 9 treatment sessions).
Participants will be considered non-completers if they
miss more than 2 treatment sessions, or if they fail to
complete the course of treatment within five months
from assessment. Therapists will make at least 3
attempts to reschedule missed appointments, followed
by a handwritten note two weeks after the last phone
contact to i) acknowledge client’s decision to leave treat-
ment, ii) encourage return to treatment, and iii) provide
information about how this can be achieved. Participants
who nevertheless choose to discontinue treatment will
be contacted for post and follow up assessments calcu-
lated as if treatment were completed 3 months from the
initial assessment.
Treatment and treatment sites
Treatment will be provided at the Emotional Health Clinic,
Centre for Emotional Health, Macquarie University, or
Drug Health Services at Royal Prince Alfred Hospital
(Sydney South West Area Health Service) and comprise
one pre-treatment session followed by 9 weekly sessions.
Two additional supplementary sessions can be used at
treating therapist discretion to deal with crises that may
emerge. The therapeutic approach will integrate CBT
skills with a motivational interviewing style. Participants
will complete monitoring diaries daily (recording the
number of drinks consumed and rating their mood,
anxiety and craving for alcohol), read educational material
and complete take home tasks. The treatment goal is
short-term abstinence (≥3 months), with participants
selecting individual goals within recommended drinking
guidelines beyond that period.
After an initial “washout” period of abstinence (≥
1 month), goals for alcohol reduction will be determined
collaboratively. Thus, participants may select a goal of
abstinence, or controlled use within recommended
drinking guidelines. Offering a choice of treatment goals
will facilitate the inclusion of participants with various
levels of dependence and decrease the risk of early
drop-out [93].
Participant retention
Participant retention will be maximised through a range
of methods. Participants will be asked to provide at least
two alternative contacts (e.g., Family member, partner or
professional with whom they have regular contact) in
addition to their own phone number and address, and if
applicable email address. Regular contact (including
study information letters, birthday cards and appoint-
ment reminder messages) with participants prior to,
during and after their treatment will be maintained up
until the final assessment at 6 months post treatment.
During this time alternatives for data collection may beemployed where they are in line with study protocol (e.g.,
conducting interviews by phone or email, or conducting
sessions at sites more convenient for participants – e.g.,
home visits). Participants will be reimbursed $25 for their
time attending follow-up assessments.
Pre-treatment session
The aim of the pre-treatment session of motivation
enhancement therapy is to place an unequivocal focus
on the importance of addressing drinking and commit
to an initial “washout” period of abstinence (≥ 1 month).
There is little evidence that without substantial changes
to substance use patterns treatment for anxiety disorders
can be successful. This session is also designed to engage
the individual in the treatment process at this crucial
stage. In this session, which is based on the work of
Miller et al. [94,95], the goal is to provide personalised
feedback of the assessment of alcohol-related difficulties,
check participants’ progress and increase or consolidate
their commitment to reduced drinking and treatment in
general; the session will also orient the person to the
treatment program and introduce daily monitoring. A
consultation with a medical practitioner will be orga-
nised to assess suitability for pharmacotherapy with
naltrexone (50 mg daily). Participants will be reimbursed
for costs associated naltrexone should it be prescribed.
Treatment for alcohol use problems only
The components of this widely used CBT intervention
include [96,97]: orientation to treatment approach;
assessing high risk situations; coping with cravings and
urges; managing thoughts about alcohol and drinking;
problem solving; drink refusal skills; planning for emer-
gencies; seemingly irrelevant decisions; dealing with a
lapse and relapse prevention.
Combined integrated treatment for alcohol use problems
and social anxiety disorder
Based on the work of Rapee [47,51], Monti et al. [97]
and our own review of the literature [62], we have deve-
loped an integrated cognitive behavioural treatment for
comorbid social phobia and alcohol use disorders [63].
The intervention is based on a unified model of the
interplay between social anxiety disorder and drinking.
Initial sessions provide information about drinking and
social anxiety disorder and their interaction, encourage
awareness of individual triggers for drinking and anxiety
through reflection on diaries and begin graded exposure
and behavioural experiments within session as well as
teaching techniques for challenging unhelpful thoughts,
refusing drinks, and managing anxiety and cravings.
Focusing on successes achieved during sessions helps to
maintain motivation. Subsequent sessions extend graded
exposure to more advanced behavioural experiments to
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techniques to build self-efficacy and self-mastery over
anxiety and drinking. Detailed participant and therapist
manuals have been developed and will be available from
the authors at the completion of the trial.
Clinical supervision of the treating therapists will be
provided for 1 hour per day with the 1st or 2nd author in
order to assure the quality and fidelity of the interven-
tions. Both AJB & CS are experienced clinical psycholo-
gists with additional training and experience in clinical
supervision.
Safety net
Participants who show deterioration in functioning
requiring residential or psychiatric treatment will be
referred to the appropriate specialist treatment services
(anxiety clinics, psychiatric services or alcohol and other
drug services). They will remain in the study but their
outcome will be designated as relapsed (for anxiety, alco-
hol or both as appropriate). Either the last point carried
forward or multiple imputation will be used to estimate
possible scores so as to include these participants in
analyses.
Treatment integrity
A random selection of 20% of sessions will be audio-taped
and rated for compliance with the treatment manual by
an independent clinician (PhD level Clinical Psychologist)
blind to treatment condition. The Cognitive Therapy Scale
[98] will be employed to assess therapist competence.
Follow-up
At the end of treatment and at three and six months after
treatment completion, participants will be reassessed by
an experienced independent research assistant blind to
treatment condition. Participants will be reassessed on the
main outcome measures in addition to the Drinker
Inventory of Consequences (DRINC) [89], Kushner’s
Alcohol Outcome Expectancies Questionnaire [74], the
OTI, the Penn Craving Scale [77], Alcohol Expectancies
Social Anxiety (AESES) [91], University of Rhode Island
Change Assessment (URICA) [79], and the Health Service
Utilisation questions [80].
Analyses
Random effects regression models will be used to com-
pare the efficacy of the treatment conditions on outcome
measures from an intention to treat perspective. Ran-
dom effect regression models (also known as hierarch-
ical linear or mixed models) have been used in clinical
trials involving relapse, and are suited to repeated
measures, missing observations, and longitudinal data
[99]. Random effects regressions can also account for
variance associated with the clustering found with grouptreatment and multiple treatment sites. Cox regression
will be used to determine time from baseline to first
drink, time to first heavy drink. Last-point carried for-
ward or multiple imputation will be used to determine
the scores of participants who drop-out and are not
located at follow-up.Determination of sample size
A sample size of 168 will be required to identify a mo-
derate effect size of 0.5 between treatment groups, in a
regression model with power = 0.8, alpha = 0.05. An
additional 32 participants will be included to allow for an
attrition rate of 20% during follow up. The total sample
size required is therefore 200. This attrition rate is based
on our recent experience in an alcohol dependent popula-
tion with a high prevalence of comorbidity [53].Discussion
Alcohol use disorders and social phobia are commonly co-
morbid despite epidemiological and basic science findings
that the two disorders interact to produce greater disabil-
ity and poorer treatment outcomes. Existing clinical trials
[4,5] indicate that alcohol focused treatment will give the
best result. These trials did not test integrated treatments
based on research into the mechanisms that may underlie
the comorbidity and probably treated samples with severe
alcohol dependence. Thus this trial will examine an inte-
grated intervention based on basic cognitive and beha-
vioural research in a sample with a range of severity of
alcohol use disorders. It is hypothesised that this novel
integrated package of motivational interviewing and
cognitive behavioural therapy will lead to better overall
outcomes across drinking, social anxiety and quality of
life. In addition those with more severe levels of alcohol
dependence are hypothesised to achieve relatively less
benefit from the novel intervention than intervention
focused on alcohol alone. This paper describes the trial
protocol; companion papers describe the research and
clinical basis for the contents of the intervention [63] and
the intervention itself is documented in detailed therapist
and participant manuals.
The proposed study addresses how individuals with
comorbid alcohol use disorders and social phobia are
best treated. Through the development and testing of
the proposed intervention, the study could potentially
define appropriate treatment for adults affected by these
problems.
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